drugset / Trial / NCT04073680
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study aims to test the hypothesis that combining serabelisib, a PI3K alpha isoform inhibitor, with an SGLT2 inhibitor, canagliflozin will improve efficacy in the treatment of patients with advanced solid tumors.
Timeline
- Start
- 2020-09-01
- Primary completion
- 2021-07-15
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CANAGLIFLOZIN ANHYDROUS | Small molecule | 300 mg | Oral |
| Subject | Serabelisib | Small molecule | 600 mg | Oral |
| Subject | Serabelisib | Small molecule | 900 mg | Oral |
| Subject | Serabelisib | Small molecule | 1200 mg | Oral |